The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated the relative frequency of these four criteria in a group of 170 pre-PMF patients and compared them to 225 ET cases. More than 91% of pre-PMF cases showed one or more of these features required for diagnosis, by contrast with only 48% of ET patients. According to clinical data the cumulative risk of progression to advanced/overt PMF in pre-PMF was 36.9% after 15 years.
| I N T R O D U C T I O N
The World Health Organization (WHO) classification for myeloproliferative neoplasms (MPNs) recognizes pre-fibrotic/early primary myelofibrosis (pre-PMF) as a prodromal stage of overt PMF, 1 an entity which requires distinction from essential thrombocythemia (ET). 2 Despite clear differences between these subentities in their clinical phenotypes, presenting bone marrow (BM) morphology and prognosis [3] [4] [5] both, the clinical criteria 6 as well as the morphological features as defined by the 2008 WHO classification 1 have been subject to some criticism in regard to their reproducibility and accuracy in defining MPN subtypes. [7] [8] [9] This uncertainty may be the reason why this MPN subtype was not included in the proposed diagnostic scheme according to the original and 2014 updated British Committee for Standards in Haematology (BCSH) criteria for PMF. [10] [11] [12] The 2008 WHO clinical diagnostic criteria for pre-PMF require the presence of at least two of the following parameters: leukoerythroblastosis, increased serum lactate dehydrogenase (LDH), anemia and splenomegaly. 1 The ongoing debate about the clinical criteria and BM features required for the diagnosis of pre-PMF [13] [14] [15] [16] [17] [18] prompted a revision that added the presence of a clonal marker (or abnormal karyotype) or absence of reactive BM fibrosis to this set of minor diagnostic criteria. 19 This revision was recently modified and replaced leukoerythroblastosis as a criterion with leukocytosis 11x 10 9 /L. In addition, only one of the minor clinical parameters is now needed to establish the diagnosis of pre-PMF according to the 2015 proposed 20 and 2016
finally accepted WHO criteria. 21 The frequency of these clinical parameters in pre-PMF in comparison to WHO-defined ET and their impact on prognosis is unknown.
The aim of this study was therefore to compare the relative frequency of the 2016 revised WHO minor clinical criteria between pre-PMF and ET in a clinico-pathologically characterized MPN cohort. Furthermore, we investigated the impact of these four minor criteria on survival in pre-PMF and in ET. All patients who fulfilled the inclusion criteria and in which information on all four parameters were available, were included in the study.
| P A T I E NT S A ND M E T H O DS
Continuous variables are described as median and range due to mostly asymmetric distributions and compared between groups using
Mann-Whiteny-U test. Categorical variables are described as counts and percentages and compared between groups using Chi-squared tests. Overall survival is described graphically using Kaplan-Meier estimates and compared between groups using log-rank tests. In a subset of patients (pre-PMF n 5 84 and ET n 5 109), molecular data were used to calculate the impact of JAK2 and CALR.
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Institutional research ethics committees approved the study protocol, and written informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
| R E S U L T S 3.1 | Frequency of minor criteria in pre-PMF and ET
In total, 170 patients with pre-PMF and 225 patients with ET fit the inclusion criteria. The patient characteristics are summarized in Table 1 .
/L) at diagnosis was found in most pre-PMF cases (84.1%) and was associated with lower median age (64.8 vs.
72.7 years, P 5 .034).
Comparison of the relative frequencies of the newly proposed minor clinical parameters including anemia (hemoglobin <13 g/dL and <12 g/dL in men and women, respectively), splenomegaly, leukocytosis
/L) and LDH above the institutional limit) showed significant differences between pre-PMF and ET cases ( Table 2) . LDH levels were most frequently elevated in pre-PMF, followed by an increased leukocyte count. Only 8.8% of pre-PMF patients failed to
show one of the selected clinical features required for pre-PMF diagnosis (Table 3) , while 52.0% of ET patients did not meet any of these clinical criteria. Because the WHO definition of pre-PMF includes patients presenting with reticulin fibrosis grades 0 and 1, we also investigated any possible relationships between fiber grade and the incidences of the minor criteria stratified for fiber grade. However, no significant differences could be seen between the two groups, neither in the number of minor clinical criteria nor in the expression of any of the criteria.
| Impact of minor criteria on overall survival
Median age at diagnosis was 66.1 years in pre-PMF and 59.0 years in ET (P < .001). The overall time under observation was 1,100 patient years in pre-PMF and 2,157 patient years in ET. Median follow-up was 9.0 years (quartiles 4.0 to 13.6). /L at diagnosis, the cumulative risk rate of progression to advanced/overt PMF after 10 years was 59.6%. In pre-PMF patients with fiber grade 1 at diagnosis, this cumulative risk rate Overall survival between pre-PMF and ET was significantly different (median 11.9 vs. 22.2 years, P < .001, Supporting Information Figure S1 ). We fitted cox regression models to analyze the impact of the presence of a minor criterion at diagnosis adjusted for diagnosis (pre-PMF vs. ET), age at diagnosis and center. Of all four minor criteria only leukocytosis was a statistically significant predictor of survival in these patients (HR 2.14, 95% CI 1.29-3.56, P 5 .003). Stratified by diagnosis, the instantaneous risk (hazard) of overall death for WBC 11 3 10 9 /L compared to WBC <11 3 10 9 /L is 2.6-fold in ET (95% CI 1.3-to 5.3-fold, P 5 .008) and 1.6-fold in pre-PMF (95% CI 0.8-to 3.0-fold, P 5 .173). However, this difference was not statistically significant (P 5 .305 for interaction, Supporting Information Table S1 ). Patients expressing a higher number of minor criteria at diagnosis showed a significantly worse outcome. Since the number of minor criteria increased with older age, this association was diminished and lost statistical significance after adjustment for age, diagnosis and centers.
We also analyzed the impact of mutational status on overall survival in pre-PMF and ET in a subgroup of patients. While survival was significantly negatively impacted by the presence of the JAK2 mutation in pre-PMF patients in comparison to CALR positive patients (P 5 .001, Figure 1 ), no such difference could be seen in ET patients (P 5 .128). 
| DISCUSSION
The present study shows that the newly proposed minor clinical criteria for pre-PMF are highly prevalent in this entity. The most common feature was an elevated LDH, which underscores the importance of this marker in MPNs. Only about 9% did not reveal any of the features at time of diagnosis. Therefore, we cannot follow the statement expressed in a recently published overview on MPNs that "in clinical practice, not uncommonly, one may face a patient who presents with thrombocytosis, has a BM biopsy suggestive of pre-PMF but lacks any of the minor criteria". 26 However, these few cases should probably be monitored closely and their diagnosis re-evaluated at a later time point, in particular in situations where histomorphology leaves little doubt about the diagnosis. In our cohort, less than 50% of ET patients also showed one or more of the minor clinical criteria. This underlines further the central role of the BM biopsy in the distinction between pre-PMF and ET. 3, 5, 14, 16, [27] [28] [29] Accurate analysis according to the published WHO guidelines, 1 seems to leave little room for confusion as the morphology of the two diseases is quite distinct and the presence of one or more minor criteria would hardly alter a clear-cut diagnosis. After all, the restriction to only one of the clinical criteria aims to confirm the histological diagnosis, but not to establish it. 20, 21 In our pre-PMF cohort the cumulative incidence of progression to overt PMF at 15 years was 36.9%. This number is substantially higher In our investigation, there was a trend for older age in the presence of minor clinical criteria. Due to the relatively low case numbers in different subgroups, any age-adjusted analysis of the impact of the minor criteria on the overall survival can only be of exploratory nature.
However, our study highlights two important trends. First, pre-PMF tends to have a worse outcome than ET in general, regardless if a minor criterion is present or not. Second, our data are highly suggestive that the presence of minor criteria at diagnosis may have an impact on survival in both entities, which warrants further investigation in larger cohorts and the incorporation of these features into possible risk scores in the future.
Molecular characterization showed a relevant impact on survival in pre-PMF but not ET, with CALR being a more favorable mutation than JAK2. This finding confirms and extends a multicenter study on overt PMF 32 and recently reported findings especially regarding CALR type 1 30 and supports the notion that pre-PMF is separated from ET and a prodromal stage of overt PMF. 33, 34 The concept of prodromal MPNs has been endorsed by the WHO classification, implying a stepwise evolution of disease. Histology of the BM and presence of clinical features play a pivotal role for diagnosing pre-PMF. 35 As has been demonstrated by follow-up examinations including repeatedly performed BM biopsies, PMF initiates with a hypercellular phase showing a normal fiber content (fiber grade 0) 18, 22 and terminates in advanced/overt PMF (fiber grade 3). 22, 33, 36 However, dynamics and course including adverse events are unpredictable and fibrogenesis is not significantly inhibited by standard therapy. 33, 37 As previously mentioned the existence of pre-PMF has been disputed repeatedly. 7, 10, 11 39 Moreover, basic assessment of BM features need a proper standardization 27 for histological pattern recognition 5, 17 and has been the subject of confusion in the past. Other reports tried to address these problems 9 and could show that, if a systematic approach was followed, high consensus rates between pathologists and a relatively small number of unclassifiable cases resulted. 28, 29, [40] [41] [42] In conclusion, our data show a high reproducibility of the newly The registry was financially supported by Novartis and AOP Orphan Pharmaceuticals.
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